2015
DOI: 10.1007/s10067-015-2865-6
|View full text |Cite
|
Sign up to set email alerts
|

Characteristic features of tacrolimus-induced lung disease in rheumatoid arthritis patients

Abstract: This paper aims to study the background and clinical characteristics of tacrolimus (TAC)-induced lung disease. A case of a rheumatoid arthritis (RA) patient who developed TAC-induced interstitial lung disease (TAC-ILD) is reported. The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) website was searched for cases of TAC-ILD and its prevalence among all cases of TAC-related adverse events. As for cases of TAC-ILD, its underlying disease, preexisting lung diseases, and fatal outcome were also searched… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
10
0

Year Published

2016
2016
2019
2019

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 21 publications
(10 citation statements)
references
References 11 publications
0
10
0
Order By: Relevance
“…Azathioprine and mammalian target of rapamycin inhibitors (mTOR, e.g., Sirolimus and Everolimus) are those at greater risk for pulmonary complications. A few reports suggest that Tacrolimus and Mycophenolate mofetil may also lead to lung injury [70][71][72].…”
Section: The Occurrence Of Lung Diseases After Kidney Transplantationmentioning
confidence: 99%
“…Azathioprine and mammalian target of rapamycin inhibitors (mTOR, e.g., Sirolimus and Everolimus) are those at greater risk for pulmonary complications. A few reports suggest that Tacrolimus and Mycophenolate mofetil may also lead to lung injury [70][71][72].…”
Section: The Occurrence Of Lung Diseases After Kidney Transplantationmentioning
confidence: 99%
“…So far, cyclophosphamide, bleomycin, carmustine, statin, everolimus, and a few others have been implicated in drug-induced NSIP/ILD. However, tacrolimus has also been shown to cause lung injury and NSIP-like changes [19]. Our patient has been on tacrolimus since her first renal transplant and it could be one of the possible causes for NSIP changes seen in our patient.…”
Section: Discussionmentioning
confidence: 75%
“…The almost unanimous cardiac hypertrophy and pulmonary hypertension encountered in the studied group on tacrolimus suggests a role of tacrolimus in maintaining and/or initiating cardiotoxicity [5] , [36] . While tacrolimus is believed to cause cardiac hypertrophy, a recent report describes tacrolimus induced interstitial lung disease in patients with rheumatoid arthritis as well [37] , suggesting a potential role in pulmonary hypertension.…”
Section: Discussionmentioning
confidence: 99%